ReShape Lifesciences Inc.
RSLS
$2.88
$0.5925.76%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.18M | 8.01M | 8.18M | 8.05M | 8.34M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.18M | 8.01M | 8.18M | 8.05M | 8.34M |
| Cost of Revenue | 2.60M | 2.95M | 2.60M | 2.62M | 2.85M |
| Gross Profit | 4.57M | 5.06M | 5.58M | 5.43M | 5.49M |
| SG&A Expenses | 9.19M | 9.92M | 11.48M | 12.53M | 14.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.47M | 14.67M | 16.10M | 17.31M | 19.55M |
| Operating Income | -6.30M | -6.67M | -7.92M | -9.26M | -11.22M |
| Income Before Tax | -3.43M | -7.09M | -7.00M | -8.96M | -10.87M |
| Income Tax Expenses | 33.00K | 40.00K | 66.00K | 63.00K | 52.00K |
| Earnings from Continuing Operations | -3.46 | -7.13 | -7.07 | -9.02 | -10.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.46M | -7.13M | -7.07M | -9.02M | -10.92M |
| EBIT | -6.30M | -6.67M | -7.92M | -9.26M | -11.22M |
| EBITDA | -6.28M | -6.65M | -7.90M | -9.19M | -11.11M |
| EPS Basic | -212.10 | -366.45 | -464.66 | -386.98 | -295.29 |
| Normalized Basic EPS | -146.49 | -242.28 | -302.74 | -254.37 | -182.19 |
| EPS Diluted | -212.10 | -366.45 | -464.66 | -386.98 | -295.29 |
| Normalized Diluted EPS | -146.49 | -242.28 | -302.74 | -254.37 | -182.19 |
| Average Basic Shares Outstanding | 144.00K | 82.50K | 64.60K | 44.20K | 26.80K |
| Average Diluted Shares Outstanding | 144.00K | 82.50K | 64.60K | 44.20K | 26.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |